[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100507447":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":26,"responsibleParty":38,"collaborators":26,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":26,"eligibilityCriteria":45,"healthyVolunteers":42,"sex":46,"minAge":47,"maxAge":26,"enrollmentInfo":48,"targetDuration":26,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":59,"overallStatus":63,"whyStopped":26,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":26},{"fullName":5,"class":6},"Taoyuan General Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vitamin D group","EXPERIMENTAL","Oral supplementation of 1,728,000 IU vitamin D3 in 3 days",[13],"Other: Vitamin D",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo Group","PLACEBO_COMPARATOR","Oral supplementation of placebo in 3 days",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"OTHER","Vitamin D","Oral supplementation of 576,000IU\u002Fday vitamin D3 in 3 consecutive days",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Oral supplementation of placebo in 3 consecutive days.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":36,"email":37},"Yuan-Hao Ku, MD","CONTACT","+886-3 3699721","4208","darkbravo@gmail.com",{"type":39,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100507447","effects-of-vitamin-d-status-and-multiple-mega-dose-supplementation-on-health-care-disparities-in-perioperative-patients-with-hepatocellular-carcinoma-receiving-hepatectomy-100507447",false,"NCT05887505","Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy","Inclusion Criteria:\n\n* 1\\. ≥ 20-year HCC subjects receiving laparoscopic hepatectomy\n* 2.Sign the informed consent\n\nExclusion Criteria:\n\n* 1\\. Using estrogen drugs, bisphosphonates, or drugs for bone disease.\n* 2\\. Consume calcium tablets within 2 weeks before operation\n* 3\\. Sarcoidosis, multiple myeloma\n* 4\\. Pregnant women or plan to become pregnant within 3 months after surgery\n* 5\\. Autoimmune hepatitis (AIH)\n* 6\\. Early liver recurrence\n* 7\\. Used to participate in other clinical trials","ALL","20 Years",{"count":49,"type":50},120,"ESTIMATED","INTERVENTIONAL",[53],"NA","High concentrations of parathyroid hormone (PTH) are common in patients with hepatocellular carcinoma (HCC). This study is aimed to investigate effects of vitamin D status and its multiple mega-dosage supplementation on PTH and clinical outcomes in HCC patients before and after hepatectomy. It's a single-center, prospective, parallel, double-blind, placebo-controlled study for 120 eligible subjects. The subjects will receive consecutively 3-day intervention treatments from 7th day before surgery. 30-day postoperative mortality, postoperative complications, and laboratory data will be evaluated.",[56,57,58],"Hepatocellular Carcinoma","Liver Function","Postoperative Complications",[60,61,62],"Vitamin D Supplementation","Hepatectomy","Perioperative","NOT_YET_RECRUITING","2023-06-04",{"date":66,"type":67},"2023-06-06","ACTUAL",{"date":69,"type":50},"2023-06-09",{"date":71,"type":50},"2027-12-31",{"name":5,"class":6}]